Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Musfardi Rustam, Ratna Djuwita, Sudarto Ronoatmodjo, Erlina Burhan, Evi Martha, et al.
…ster on the 272 th day. The risk of T2DM group with the new regimens in the treatment of DR-TB was 10.66 times (95% CI 3.23-35.12). Whereas, the treatment on NonT2DM group with old regimen with marital status that was controlled showed a significant statistic value with value p&l…
Muhammad Rifqy Alvy Widodo, Ida Srisurani Wiji Astuti, Inke Kusumastuti, Angga Mardro Raharjo, Supangat Supangat, et al.
… comparison between the administration of individual MDR-TB regimens and short-term regimens concerning anxiety levels in MDR-TB patients at Dr. Soebandi Regional General Hospital, Jember. Methods: This was an analytical observational study with a cross-sectional design. It was c…
Yohanes Widjaja, Khairuddin Djawad, Saffruddin Amin, Widyawati Djamaluddin, Dirmawati Kadir, et al.
Abstract Introduction . Leprosy is a disease that predominantly affects the skin and peripheral nerves, resulting in neuropathy and associated long-term consequences, including deformities and disabilities. According to the WHO classification, there are two categories of leprosy,…
Yu. I. Feshchenko, N.А. Lytvynenko, M.V. Pohrebna, Yu.О. Senko, Anastasiia Lafeta, et al.
Objective — to study the programmatic results of the efficacy and tolerability of the standard combination BPaL regimen for patients with multidrug-resistant tuberculosis failures and pre-XDR-TB. Materials and methods. Treatment of patients with BPaL regimen took place within th…
Preethi Koyyana, Mohana Pradeepika Machcha, Rajasekharam Gunta, Dhilleswara Rao Pudi
… reduction of social stigmatization. In contrast to earlier regimens that contained injectable drugs, the World Health Organization has recommended all-oral regimens for the treatment of Multidrug-Resistant/Rifampicin-Resistant-TB since 2018, which represents a significant advanc…
Jorge Torresi, Ana Angélica Bulcão Portela Lindoso
…lable drugs. The recent implementation of bedaquiline-based regimens represents an advance in combating this condition, although few studies have evaluated the public health impact of their implementation. The present study aimed to evaluate the impacts of implementing oral regim…
Tom Decroo, MD
…nt regimen. Therefore the investigators propose to study if regimens strengthened by using high-dose first-line drugs, either a triple dose of isoniazid or a triple dose of rifampicin, are non-inferior to the WHO recommended levofloxacin-strengthened regimen. If one of both high-…
Shenjie Tang, MD
…udy is to evaluate the safety and efficacy of two shortened regimens for newly diagnosed smear positive drug susceptible pulmonary tuberculosis in comparison to World Health Organization recommended standard 6-month regimen. 1. Design: The study is a multi-center, randomized,con…
Susan Shin-Jung Lee, M.D., Ph.D.
The development of efficacious, safe, and shorter treatment regimens could significantly improve TB management and treatment success rates. This prospective, 3-year, single arm study is to evaluate the efficacy and safety of a short-course, 4-month regimen including isoniazid(H),…
Mutong Fang, Sinian Li, Xiangxiang Liu, Guoju Shao, Zhi Mao, et al.
…ety between bedaquiline(Bdq) and non-bedaquiline containing regimens for treatment of Pre XDR-TB. Meanwhile, we analyze the outcomes among different Bdq duration and total regimen duration. P < 0.05 is significantly different, GraphPad prism 5.0 software package was used to pr…
Vincent M. Balanag, Vivian Lofranco, Mariquita J. Mantala, Mary Rosary T. Santiago, Patrice Jamie E. Cabasis, et al.
… have shown the potential benefits of adding bedaquiline to regimens for drug-resistant TB (DR-TB). In search of more effective regimens for DR-TB, bedaquiline was introduced in the TB program in the Philippines under operational research to assess its effectiveness, safety, and …
Pankaj Jorwal, Anivita Aggarwal, Parul Kodan, Nitin Gupta, Sudeshna Ghosh, et al.
…e difficulty in its diagnosis, the long course of treatment regimens is associated with multiple side-effects, poor compliance and undesirable rate of a positive outcome. Before the availability of newer treatment regimens and newer drugs, positive outcomes in patients with XDR-T…
H. Mursaloglu, Can Akın, Cansu Yilmaz, Pınar Ergenekon, Yasemi̇n Gökdemi̇r, et al.
…redictors of treatment failure, the efficacy of eradication regimens and long-term clinical outcome in our CF center. <b>Methods:</b> 309 patients were involved in the study. All sputum cultures collected between 2015-2019 were reviewed. Clinical findings, demographics and eradic…
Susan Shin-Jung Lee, MD, PhD
…The development of efficacious, safe, and shorter treatment regimens could significantly improve treatment completion rate and reduce transmission of TB. The current treatment guidelines for drug-susceptible TB from the World Health Organization (WHO), American Thoracic Society (…
Natalia Yatskevich, G. L. Gurevich, E. M. Skryagina, Elmira Gurbanova
… to evaluate the effectiveness of 39- and 24-week treatment regimens in patients with multiple drug resistant or rifampicin-resistant tuberculosis (MDR/RR-TB). Subjects and Methods . We evaluated the effectiveness of 39- and 24-week treatment regimens containing bedaquiline, levo…
P Muneera, Grinish Tamakuwala, Jignesh Gengadiya, Parul Vadgama
…inal outcome, and ADRs in RR-TB patients taking shorter MDR regimens. Materials and Methods: Prospective observational longitudinal study which was carried out in the Department of Respiratory Medicine Department, New Civil Hospital, Surat from January 2019 to June 2020. All pati…
Rathinam Sridhar
…ntroducing short-course 9–12 months all oral Bdq containing regimens with specific inclusion and exclusion criteria.[1] All oral Bdq-based shorter regimens significantly improved sputum culture conversions and treatment success while reducing mortality and treatment failures.[2] …
Muhamad Frendy Setyawan, Ni Made Mertaniasih, Soedarsono Soedarsono
BACKGROUND: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in t…
Edmund Shen, Mikanda Kwabisha Kunda, Stephane Mpinda, Allison LaHood, Letizia Trevisi, et al.
…. Historically, effective therapy was hindered by prolonged regimens and drug toxicity. Recent clinical trials and observational studies demonstrated the potential of shortened all-oral regimens in improving treatment outcomes, leading the WHO to recommend several standardized 6 …
Mireille Avilaw Mpwate, Eddy Mampuya Mbambu, Christian Nzanza Matanda, Gabriel Mabwaka Lema, Michel Kaswa, et al.
…me between the two groups of patients on AG and bedaquiline regimens. The double-difference method was estimated using regression with fixed-effects. A p value Results: The degree of hearing loss was similar between the two groups at the first month [AGs (28 dB) vs BDQ (30 dB); p…
Stephen H Gillespie, MB BCh BAO MD DSc, Andrew Nunn, BSc MSc, Sarah K Meredith, MB BS MSc, Timothy D McHugh, BSc PhD CSi, Ali Zumla, BSc MBChB MSc PhD, et al.
…erculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substit…
Rahul Verma
…ifficult and challenging treatment. There are two treatment regimens for MDR-TB treatment. Objectives: To compare the predisposing risk factors and treatment outcomes in two different drug regimens for the treatment of MDR-TB. Material and methods: A field based longitudinal stud…
Christoph Lange, Yousra Kherabi, Lorenzo Guglielmetti, Raquel Duarte, Gunar Günther
In the recent manuscript by Günther G. et al. “Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe”, published in this journal ( 1 Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C; Tuberculosis Network European Tri…
Kendra Brett, Melissa Severn
…r treating active tuberculosis (TB), some 4-month treatment regimens may be as effective and safe as the standard 6-month treatment regimen. However, there are also 4-month treatment regimens that seem to be less effective than the 6-month treatment regimen for treating active TB…
Tmp Nguyen, T.H.M. Le, C.S.C. Merle, L. Guglielmetti, N.L. Nguyen, et al.
… in the same year. 1 In 2025, the WHO recommended different regimens for RR-TB patients without confirmed fluoroquinolones (FQ) resistance, one of which is a 5-drug 9-month treatment regimen, based on results of the endTB clinical trial.This so called BCLLfxZ regimen includes bed…